Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

In connection with the contemplated merger transaction between Reneo Pharmaceuticals, Inc. (the "Company") and OnKure, Inc. and the cessation of the Company's historical drug development efforts, the Company terminated the employment of Ashley F. Hall, J.D., the Company's Chief Development Officer, effective as of September 13, 2024. In connection with Ms. Hall's termination, she will be entitled to receive the severance benefits under the Company's severance benefit plan previously disclosed under the heading "Potential Payments Upon Termination or Change of Control" in Item 11 of the Company's Amendment No. 1 to its Annual Report on Form 10-Kfor the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 26, 2024.